Healthsonix Inc. DL-,001

Meine Einstiege  waren zwischen 0,11 und 0,209.
Somit bin ich leider noch im Minus.
Aber ich bin guter Hoffnung. Die Wehen setzen schon ein und im September were ich dann auf der Promotiontour gebären *g*  

 

 

 

Und null gehandet seit über einem Monat.
Aber wie gesagt, promotet wird im September  

 

0,27 US Cent ist doch das einzige was interessiert.
Wer handelt Healthsonix schon in Frankfurt?  

 

FOR IMMEDIATE RELEASE:

HealthSonix Names Cohen Consulting as Agency of Record
IRVINE, CA - HealthSonix, Inc. (OTC: HSXI; FRANKFURT: H7S)- MARKET WIRE) -- 08/07/2007 - announced today that it has named Cohen Consulting as its Agency of Record. Cohen Consulting will provide a full service public relations and financial communications program.

Commenting on the announcement, Dieter Doederlein, Vice President of Corporate Development, said, "We have chosen Cohen Consulting because of Mark's outstanding track record of enhancing shareholder value for many emerging growth companies. As our business continues to grow, and with an expected move to a senior exchange, we are now embarking on a program to dramatically increase our exposure to the Wall Street investment community."

"We are very excited about working with HealthSonix, Inc. and look forward to implementing a comprehensive financial communications strategy for this company. They will be a valuable addition to our growing client roster of publicly traded companies," said Mark Cohen, Chief Executive Officer of Cohen Consulting.

About HealthSonix, Inc.

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

About Cohen Consulting

Headquartered in New York City, Cohen Consulting is a full service Investor Relations and Public Relations firm which specializes in assisting emerging growth companies across all industries to expand their exposure to Wall Street. Since its inception, Cohen Consulting has achieved unparalleled success for their clients.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Dieter D. Doederlein
1-877-622-2121
info@healthsonix.com

SOURCE:  HealthSonix Inc.

 

spread wächst  

 

 

HSXI macht ständig Fortschritte und erfüllt nach und nach alle Voraussetzungen, um die gesteckten (hohen) Ziele zu erreichen.

Der Online-store läuft auch (http://www.myarthritisstore.com).

Alles in allem, weiterhin beste Aussichten auf ein sehr erfreuliches Jahresende.

************************************

IRVINE, CA--(MARKET WIRE)--Aug 15, 2007 -- HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) today announced that it has launched new packaging for its ZingiberRx pain relieving cream. The move follows 3 months of feedback from consumers, particularly the over 50 market, who prefer the easier-to-use tube rather than the jars.
ADVERTISEMENT


"According to Pain Therapeutics-Drugs, Markets and Companies, October 2005, the worldwide market for pain is estimated at U.S. $50.0 billion for 2005 and is expected to increase to U.S. $75.0 billion by 2010," said Dieter D. Doederlein, Vice President of Corporate Development for HealthSonix. "And according to the Nicholas Hall DB6 database, the global market for OTC sales of topical analgesics is estimated at U.S. $2.6 billion. With a market this size, it was imperative that we address all consumer concerns and this packaging change reflects our commitment and ability to respond quickly to changing trends."

Customers can order ZingiberRx by calling HealthSonix, Inc. on a toll free line at 1-877-622-2121, or by ordering on line at MyArthritisStore.com. HealthSonix is also launching regional sampling programs to increase awareness and encourage trial use of ZingiberRx, particularly among the elderly suffering with arthritis and people active in sports and fitness organizations.

HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.



Contact:
Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact



--------------------------------------------------
Source: HealthSonix, Inc.
 

 

wird es diese Schnäppchenkurse geben ?

***********************

IRVINE, CA--(MARKET WIRE)--Aug 22, 2007 -- HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) today announced that it has retained Synergy Management Group to promote its new line of products and services. With regional offices in Canada, and Associates across North America, Asia and the EU, Synergy's family of professional Business and Economic Development Consultants has served the private and public sectors, and government, for over twenty years.

"Synergy brands, develops consumer awareness and creates market interest, including through editorial media placements, in products ranging from technology to consumer items," stated Mr. Jay Silverberg, President and CEO of Synergy. "Our team," he continued, "has served a number of Fortune 500 companies, in national and international markets. We all feel strongly that HealthSonix, and ZingiberRx should have a significant impact in the marketplace."

"We are indeed pleased to be working with Synergy and feel confident that our company will be in an even stronger position to implement its business plan for 2008 and beyond," stated Dieter Doederlein, Vice President, Corporate Development at HealthSonix. "The cornerstone of our growth plan is the international launch of ZingiberRX, pain relieving cream and our next-generation enSonix@home, sound pressure wave technology and the related delivery systems. This requires a focused and aggressive marketing team that is familiar with the challenges of new, groundbreaking technology. Synergy certainly met all our selection criteria."

"We feel that HealthSonix has a medical breakthrough that will have a worldwide impact, and are looking forward to being part of their ambitious growth plans," said Jay Silverberg, President & CEO, Synergy Management Group Ltd. "Our depth of experience in marketing leading-edge technology was a factor and the fact that our Technology team brings together a wealth of strategic media relations experience to an ever-growing and highly diverse practice was viewed as a key asset and good fit for this exciting assignment," said Mr. Silverman.

HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.



Contact:
    Contact:
    Dieter D. Doederlein
    1-877-622-2121
    Email Contact
     


--------------------------------------------------
Source: HealthSonix, Inc.  

 

HealthSonix Sampling Program for ZingiberRx Pain Relieving Cream Draws Positive Reviews
Tuesday August 28, 8:01 am ET


IRVINE, CA--(MARKET WIRE)--Aug 28, 2007 -- HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) today announced that a sampling program for its ZingiberRx pain relieving cream is underway and that the product is being received with a great deal of enthusiasm, particularly among sports enthusiasts and the still active over 50 crowd suffering with chronic pain and stiffness in their joints.
ADVERTISEMENT


"We are getting a flood of positive reviews from people who have tried ZingiberRx," said Dieter D. Doederlein, Vice President of Corporate Development for HealthSonix. "We had high expectations for the product, and the results to date indicate that our expectations will be exceeded."

ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.

The company encourages Individuals, as well as shareholders, who experience chronic or acute pain to participate in the sampling program by ordering a free sample of Zingiber Rx by sending a "free sample request" email to INFO@HEALTHSONIX.COM or by calling the Company tool free at 1-877-622-2121. Orders may be placed on line at: www.MyArthritisStore.com.

HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
 

geil!  

Dein Wort in Gottes Ohr. :o)  

steigt aber langsam aber stetig immer höher.Geht hierbei um Gesundheitswesen glaube ich.Was auch immer die machen ,das mit dem Medizinkrempel sollte doch immer gut laufen.Merk gerade muss meine Pille schmiessen ,echt fett die Drogen.;)  

Von 0,27 USD zu 0,255 zu 0,25 ist eine Fallende.
Aber wahrscheinlich liegst Du nach der Droge quer und deswegen indentifizierst Du das als Steigende! *lach*  

ich bin zu 0,23 rein und werde mit Sicherheit das Handtuch nicht schmeissen.Selbst wenn das Ding abschmiert ,werde ich nicht verkaufen.Denn wie allzu oft ,siehe da von Geisterhand ,geht dann natürlich just in diesem Moment der Cahrt hoch zu den Englein.Ich bleib drinn und freue mich jetzt schon auf meinen aufgeschwollenen Broker.MfG buran  

einige noch grosse Augen machen. Im September geht das Marketing und der Vertrieb richtig los, das angekündigte JV startet auch am 03.09.07.

Auch in Deutschland wird es ab Herbst mehr Aktivitäten seitens HSXI geben, dies wurde mir auf Nachfrage mitgeteilt.

Diese Creme muss gut sein, wenn es kostenlose Proben gibt, ansonsten würde man dies nicht tun.

Alles eine Frage der Zeit und es macht "Bumm".

 

haben ich auch schon vor ca. zwei Wochen durch die Gerüchteküche anderer Foren erfahren ,wir können uns überraschen lassen.Der Kurs lässt uns wenigstens nicht hängen.;)  

HealthSonix Business Developments on Target
Thursday September 6, 10:50 am ET


IRVINE, CA--(MARKET WIRE)--Sep 6, 2007 -- HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) today released the following statement from Dieter Doederlein, Vice President, Corporate Development at HealthSonix.
"Due to the many contacts that we have received from shareholders and new investors requesting updates on the various initiatives that were announced during the summer, we are pleased to provide the following summary of the stages where those initiatives presently are, and when we expect completion:



   1.  The infomercial for the enSonix@home unit is in final production
       stage: the production company is doing some last minute additional
       'in the field' shooting before the final edits are done. Revised
       air time is early October;

   2.  The enSonix@home device is undergoing QC testing for efficacy,
       overall performance and durability. Sign offs to start the
       manufacturing are expected within 30 days.

   3.  The in the field joint marketing program with a pharmaceutical
       company is scheduled to commence mid September, at which time the
       name of the company will be in the public domain;

   4.  HealthSonix plans to apply for a listing on the AMEX before the
       end of this calendar year; all the necessary documentation to be
       filed with the regulators is being prepared towards that end.

   5.  Management has scheduled IR meetings in New York, starting
       September 18th, right through the end of November to acquaint
       institutions and retail brokerage houses with the HealthSonix
       products and services;

   6.  The ZingiberRx sampling program continues to yield good results:
       retail listing is underway in a test market using local newspapers
       to distribute coupons directing the audience to pharmacies.

"We are moving forward on many different fronts and the positive feedback and the encouragement that we have received from our partners and patients serve to confirm that we are on the right track. We are looking forward with much anticipation to an exciting fall and winter," said Doederlein.

HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

ADVERTISEMENT


Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.



Contact:
    Contact:
    Dieter D. Doederlein
    1-877-622-2121
    Email Contact